No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
- PMID: 20739945
- PMCID: PMC3042679
- DOI: 10.1038/jid.2010.243
No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
Similar articles
-
Squamous cell carcinoma developing in epidermolysis bullosa dystrophica.Int J Dermatol. 1991 Oct;30(10):718-21. doi: 10.1111/j.1365-4362.1991.tb02618.x. Int J Dermatol. 1991. PMID: 1955228 Review.
-
Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.Dermatol Clin. 2010 Jan;28(1):171-8. doi: 10.1016/j.det.2009.10.023. Dermatol Clin. 2010. PMID: 19945632 Review.
-
Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa.Acta Derm Venereol. 2001 Jun-Jul;81(3):189-92. doi: 10.1080/000155501750376285. Acta Derm Venereol. 2001. PMID: 11558875
-
Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2. doi: 10.1684/ejd.2015.2552. Eur J Dermatol. 2015. PMID: 26083672 Review.
-
Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica.Dermatol Surg. 2004 Nov;30(11):1424-9. doi: 10.1111/j.1524-4725.2004.30440.x. Dermatol Surg. 2004. PMID: 15522026 Review.
Cited by
-
Transcriptome-Guided Drug Repurposing for Aggressive SCCs.Int J Mol Sci. 2022 Jan 17;23(2):1007. doi: 10.3390/ijms23021007. Int J Mol Sci. 2022. PMID: 35055192 Free PMC article.
-
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.Clin Cancer Res. 2019 Jun 1;25(11):3384-3391. doi: 10.1158/1078-0432.CCR-18-2661. Epub 2019 Mar 7. Clin Cancer Res. 2019. PMID: 30846478 Free PMC article.
-
Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.Int J Mol Sci. 2019 Nov 14;20(22):5707. doi: 10.3390/ijms20225707. Int J Mol Sci. 2019. PMID: 31739489 Free PMC article. Review.
-
Biomarker Discovery in Rare Malignancies: Development of a miRNA Signature for RDEB-cSCC.Cancers (Basel). 2023 Jun 22;15(13):3286. doi: 10.3390/cancers15133286. Cancers (Basel). 2023. PMID: 37444397 Free PMC article.
References
-
- Christiano AM, Greenspan DS, Hoffman GG, Zhang X, Tamai Y, Lin AN, Dietz HC, Hovnanian A, Uitto J. A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet. 1993;4:62–66. - PubMed
-
- de Koning M, Quint W, Struijk L, Kleter B, Wanningen P, van Doorn LJ, Weissenborn SJ, Feltkamp M, ter Schegget J. Evaluation of a novel highly sensitive, broad-spectrum PCR-reverse hybridization assay for detection and identification of beta-papillomavirus DNA. J Clin Microbiol. 2006;44:1792–1800. - PMC - PubMed
-
- de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27. - PubMed
-
- Delle’Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, Leigheb G, Weissenborn SJ, Pfister H, Michael KM, Waterboer T, Pawlita M, Amantea A, Landolfo S, Gariglio M. High β-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol. 2009;129:1026–1034. - PubMed
-
- Feltkamp MCW, de Koning MNC, Bavinck J. N. Bouwes, ter Schegget J. Betapapillomaviruses: Innocent bystanders or causes of skin cancer. J Clin Virol. 2008;43:353–360. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical